MetaCap

Septerna (SEPN) vs Zymeworks (ZYME)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Septerna (SEPN) has outperformed Zymeworks (ZYME) over the past year, gaining 51.1% versus a gain of 8.8%. Septerna is the larger company by market cap ($1.84 billion vs $1.81 billion), about 1.0 times the size. Zymeworks converts more of its revenue into profit, with a net margin of -76.6% versus -106.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SEPN+51.06%ZYME+8.83%
+110%+48%-15%
Nov 21, 20251 yearNov 20, 2026
SEPN+80.42%ZYME+102.17%
+139%+27%-85%
Oct 21, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SEPN versus ZYME key metrics
MetricSEPNZYME
Share price$38.61$26.14
Market cap$1.84B$1.81B
1-day change-1.51%-2.68%
YTD return+38.49%-0.72%
1-year return+51.06%+8.83%
5-year return—+34.05%
P/E ratio (TTM)—49.32
Forward P/E—54.95
EPS (TTM)$-1.30$0.53
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$45.95M$105.97M
Revenue growth (YoY)+4174.51%+38.87%
Net income (latest FY)$-48.88M$-81.13M
Operating margin-148.63%-87.34%
Net margin-106.37%-76.56%
52-week high$53.34$31.97
52-week low$22.78$21.52
Distance from 52-week high-27.62%-18.24%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+53.38%+65.61%
Average volume383.96K1.09M
Shares outstanding47.55M68.70M
Employees134279
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SEPN has outperformed ZYME by 42.2 percentage points over the past year.
  • Zymeworks is more profitable, keeping -76.6 cents of every revenue dollar as net income versus -106.4 cents for Septerna.
  • Septerna grew revenue faster in its latest fiscal year (+4174.51% vs +38.87%).

About Septerna

SEPN stock →

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 134 employees

About Zymeworks

ZYME stock →

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 279 employees

SEPN vs ZYME FAQ

Which is bigger, Septerna or Zymeworks?

Septerna (SEPN) is larger, with a market capitalization of $1.84B compared with $1.81B for Zymeworks (ZYME).

Which stock has performed better over the past year, SEPN or ZYME?

SEPN returned +51.06% over the past 12 months, compared with +8.83% for ZYME (price return, excluding dividends). Past performance does not predict future results.

Are Septerna and Zymeworks in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons